-
-
-
-
-
-
-
Roivant Sciences (ROIV) and Pfizer (PFE) Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
-
-
-
-
-
-
-
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update
-
-
-
-
-
-
-
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
1,199,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

